Please ensure Javascript is enabled for purposes of website accessibility

Incyte's Eczema Drug Ruxolitinib Works in a Late-Stage Clinical Trial

By Brian Orelli, PhD - Jan 28, 2020 at 2:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

But the biotech won't release details about how well it works until later.

Results of a phase 3 clinical trial dubbed TRuE-AD2 showed that Incyte's (INCY -0.81%) ruxolitinib cream helped patients with atopic dermatitis, an autoimmune disease commonly referred to as eczema. Shares of Incyte were up about 1% on the news in early afternoon trading Tuesday.

After eight weeks of treatment, both the 0.75% and 1.5% doses helped more patients reach an Investigator's Global Assessment (IGA) score of clear or almost clear with at least a two-point improvement in IGA compared to patients using the base cream without the medication.

Incyte didn't disclose the number of patients who met the goal in each treatment group. As biotech companies are apt to do, it's saving the more-detailed data for an upcoming scientific meeting. Additional data from another phase 3 clinical trial in patients with eczema (TRuE-AD1) is also expected this quarter.

Dermatologist examining a patient's arm

Image source: Getty Images.

Ruxolitinib works by inhibiting Janus kinase proteins, which are involved in the activation of the immune system and bone marrow cells. The drug is also the active ingredient in Incyte's Jakafi, an oral tablet approved to treat polycythemia vera, myelofibrosis, and graft-versus-host disease that involve aberrant activation of the immune system or bone marrow. The cream version is also being tested in patients with vitiligo, a skin disease in which the immune system attacks pigment-producing cells, resulting in patches of skin that are white or lighter than the surrounding skin.

Incyte has also developed another oral Janus kinase inhibitor, Olumiant, with its partner Eli Lilly (LLY 0.28%). On Monday, the duo posted positive data for the drug in patients with eczema. Olumiant is already approved to treat rheumatoid arthritis.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Incyte Corporation Stock Quote
Incyte Corporation
$74.90 (-0.81%) $0.61
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$291.63 (0.28%) $0.81

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.